It’s all about the US for Jens Bager & Co.
The US is going to be the major driving force for ALK-Abello’s growth in coming years, but the company is also working with several models for penetrating the markets in China, Brazil and Russia.
by Kresten Morten Munksgaard & Henrik Tüchsen
Simplify, Innovate, Grow - those are the headlines in the strategy Danish allergy vaccine manufacturer ALK-Abello revealed last fall, and while a plan has been put in place for the two first points it is still uncertain if and how ALK will be able to perform in regards to the growth agenda.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
ALK-CEO expects great US success – eventually
For abonnenter
ALK reaches important US milestone
For abonnenter
